Shuying Shen | Health Professions | Excellence in Innovation Award

Prof. Shuying Shen | Health Professions | Excellence in Innovation Award 

 Zhejiang University | China

Dr. Shuying Shen is a distinguished research fellow at Sir Run Run Shaw Hospital affiliated with the Medical College of Zhejiang University, where she has established a strong research presence in musculoskeletal biology, molecular regulation, and osteoarthritis pathology. She earned her Ph.D. in Biochemistry and Molecular Biology in 2017 and her Bachelor’s degree in Applied Bioscience in 2012, both from Zhejiang University. Dr. Shen’s research has been continuously supported by major competitive grants, including the National Natural Science Foundation of China Excellent Young Scholars Fund, multiple NSFC General Programs, and the Zhejiang Provincial Outstanding Youth Project. Her funded projects focus on elucidating mechanisms of protein post-translational modification, chondrocyte aging, metabolic reprogramming in osteosarcoma, and non-classical regulatory pathways in chondrocyte physiology, reflecting her deep engagement with both degenerative diseases and cancer biology. Dr. Shen has made influential contributions to the understanding of noncoding RNA functions in osteoarthritis progression, osteosarcoma development and metastasis, and organ size regulation. Her work reveals how circular RNAs, microRNAs, and RNA–protein interactions shape cellular senescence, lipid metabolism, autophagy, and energy homeostasis. She has also advanced knowledge on the interplay between metabolic remodeling and epigenetic regulation in cartilage degeneration. Her publications demonstrate innovative approaches combining molecular biology, functional genomics, epigenetics, and translational models to uncover therapeutic targets for osteoarthritis, intervertebral disc degeneration, and malignancies. Dr. Shen has published 87 peer-reviewed papers, including 50 as first or corresponding author, in top-tier journals such as Nature Aging, Science Translational Medicine, Cell Research, Nature Communications, Annals of the Rheumatic Diseases, PNAS, Advanced Science, Molecular Cancer, Bone Research, and Molecular Therapy. Her research has been cited more than 3,000 times, and she holds an H-index of 37, underscoring her strong scientific influence. Through her pioneering discoveries—such as the regulation of chondrocyte senescence by palmitoylation, the role of fatty acid oxidation in osteoarthritis, circRNA-mediated metabolic control, and noncoding RNA networks in osteosarcoma—Dr. Shen has significantly advanced the field of musculoskeletal molecular medicine. Her long-term research goal is to develop novel diagnostic markers and targeted therapies for osteoarthritis and related degenerative diseases through a deeper understanding of RNA regulation, protein modifications, and metabolic homeostasis.

Profile: Scopus

Featured Publications

Wang, K., He, W., Gong, Z., Gao, J., Gao, T., Pan, N., Wu, D., Yang, Y., Li, Z., Zhao, X., Ji, M., & Shen, S. Y. (2025). ZDHHC11-mediated palmitoylation alleviates chondrocyte senescence and serves as a therapeutic target for osteoarthritis. Nature Aging.

Mei, Z., Yilamu, K., Ni, W., Shen, P., Pan, N., Chen, H., Su, Y., Guo, L., Sun, Q., Li, Z., Huang, D., Fang, X., Fan, S., Zhang, H., & Shen, S. Y. (2025). Chondrocyte fatty acid oxidation drives osteoarthritis via SOX9 degradation and epigenetic regulation. Nature Communications, 16(1), 4892.

Gong, Z., Zhu, J., Chen, J., Feng, F., Zhang, H., Zhang, Z., Song, C., Liang, K., Yang, S., Fan, S., Fang, X., & Shen, S. Y. (2023). CircRREB1 mediates lipid metabolism–related senescent phenotypes in chondrocytes through FASN post-translational modifications. Nature Communications, 14(1), 5242.

Li, Z., Zhang, W., Wei, X. Y., Hu, J. Z., Hu, X., Liu, H., Lu, J., Shen, S. Y., & Ji, M. L. (2025). TRIM15 drives chondrocyte senescence and osteoarthritis progression. Science Translational Medicine, 17(791), eadq1735.

Shen, S. Y., Guo, X. C., Yan, H., Lu, Y., Ji, X. Y., Li, L., Liang, T. B., Zhou, D. W., Zhao, J. C., Yu, J. D., Gong, X. G., Zhang, L., & Zhao, B. (2015). A miR-130a–YAP positive feedback loop promotes organ size and tumorigenesis. Cell Research, 25(9), 997–1012.

Shen, S. Y., Wu, Y. Z., Chen, J. X., Xie, Z., Huang, K. M., Wang, G. L., Yang, Y. T., Ni, W. Y., Chen, Z. J., Shi, P. H., Ma, Y., & Fan, S. W. (2019). CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene. Annals of the Rheumatic Diseases, 78(6), 826–836.

Shen, S. Y., Yang, Y. T., Shen, P. Y., Ma, J., Fang, B., Wang, Q. X., Wang, K. F., Shi, P. H., Fan, S. W., & Fang, X. Q. (2021). circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1. Annals of the Rheumatic Diseases, 80(9), 1209–1219.

Shen, S. Y., Liang, Y., Zhao, Y., Hu, Z., Huang, Y., Wu, Y., Liu, Y., Fan, S., Wang, Q., & Xiao, P. (2024). Dietary supplementation of vitamin B1 prevents the pathogenesis of osteoarthritis. Proceedings of the National Academy of Sciences, 121(30), e2408160121.

Hygon Mutavhatsindi | Infectious Diseases | Best Researcher Award

Dr. Hygon Mutavhatsindi | Infectious Diseases | Best Researcher Award

Specialist Scientist, SAMRC, South Africa.

Hygon Mutavhatsindi is a Specialist Scientist at the South African Medical Research Council (SAMRC) with a robust background in biochemistry, molecular biology, and immunology. His research explores infectious diseases, particularly tuberculosis (TB), HIV, and COVID-19, using molecular and immunological techniques. Dr. Mutavhatsindi has made significant contributions to immunology and TB research, aiming to identify non-sputum biomarkers to improve TB diagnosis and treatment outcomes. His work has earned him national and international recognition, alongside numerous grants and awards.

Profile

Scopus

Orcid

Education 🎓

Dr. Hygon Mutavhatsindi began his academic journey at the University of Venda, where he earned a BSc in Biochemistry and Biology (2009-2012), followed by an Honours degree in Biochemistry in 2013. He continued to pursue advanced studies at the same institution, obtaining an MSc in Biochemistry (2014-2015). His passion for molecular biology led him to Stellenbosch University, where he completed his PhD in Molecular Biology (2016-2019). During his doctoral studies, Dr. Mutavhatsindi focused on cutting-edge research, contributing to scientific advancements in his field.

Following his PhD, Dr. Mutavhatsindi undertook a prestigious Postdoctoral Fellowship in Immunology at the University of Cape Town (2020-2023). During this period, he deepened his expertise in immunological research, working on projects that explored the intricate mechanisms of immune response. His postdoctoral work not only advanced his academic credentials but also positioned him at the forefront of immunological science, further strengthening his research profile and contributing to ongoing scientific discussions in molecular biology and immunology.

Experience 💼

Dr. Hygon Mutavhatsindi currently serves as a Specialist Scientist at the South African Medical Research Council (SAMRC), a role he began in February 2024. In this position, he leads research efforts in tuberculosis (TB) and immunology, supervises postgraduate students, and manages multiple research projects. Prior to this, he was a Scientific Officer at the Cape Town HVTN Immunology Laboratory (May 2023–January 2024), where he conducted clinical studies and flow cytometry experiments, contributing to crucial immunological research.

Before taking on these roles, Dr. Mutavhatsindi completed a Postdoctoral Research Fellowship at the University of Cape Town (February 2020–January 2023), where his work focused on TB and COVID-19 immunology. His academic journey began as a PhD Researcher at Stellenbosch University (June 2016–December 2019), where he specialized in identifying TB biomarkers and evaluating treatment responses, building a strong foundation for his later contributions to immunology and infectious disease research.

Research Interests 🔬

TB Biomarkers: Focuses on identifying reliable biomarkers for tuberculosis diagnosis and monitoring treatment efficacy.

Non-Sputum Diagnostic Methods: Investigates blood- and saliva-based biomarkers to develop non-sputum diagnostic alternatives for TB, making diagnosis easier in low-resource settings.

Immunological Responses: Studies the immune system’s response to infectious diseases, with an emphasis on TB, HIV, and COVID-19.

Infectious Disease Immunology: Explores the interactions between pathogens and host immune responses to enhance understanding of disease progression and treatment outcomes.

TB Treatment Monitoring: Aims to develop new methods for tracking patient progress during TB treatment through biomarker discovery.

Cross-Disease Immunology: Compares immune responses across different infectious diseases, seeking common biomarkers and pathways for broader diagnostic and therapeutic applications.

Awards 🏆

Awards and Grants:

UCT CIDRI-Africa Postdoctoral Fellowship (2020-2022)

Fogarty HIV-Associated TB Training Program (2020-2022)

NRF Postdoctoral Fellowship (2021-2022)

SAMRC Doctoral Internship Scholarship (2017-2019)

NRF PhD and Masters Scholarships

Publications Top Notes 📚 

Validation and optimisation of host immunological bio-signatures for a point-of-care test for TB diseaseFront. Immunol., 2021. link

Identification of novel salivary candidate protein biomarkers for tuberculosis diagnosisTuberculosis, 2021. link

Protocol to quantify and phenotype SARS-CoV-2 specific T-cell responseStar Protocols, 2022. link

Blood and site of disease inflammatory profiles in HIV-1-infected pericardial tuberculosis patientsOFID, 2023. link

Application of cerebrospinal fluid host protein biosignatures in the diagnosis of tuberculous meningitis in childrenMediators of Inflammation, 2019. link